Ph 1b trial of elraglusib, retifanlimab, and mFOLFIRINOX combo as 1L therapy in advanced pancreatic adenocarcinoma initiated August 12, 2025
Enrollment Open for 160 mg Dosing Cohort of Tuspetinib in Ph 1/2 TUSCANY Trial of 1L Triple Drug Therapy in induction-ineligible AML patients August 12, 2025
RP2D in Ph 1 Study of SENTI-202 for the Treatment of R/R Heme Malignancies, Including AML, Determined August 12, 2025
Patient death triggers switch to standard FC Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in 1L Consolidation for LBCL August 5, 2025
First Patient Dosed in Ph 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer August 5, 2025
Clinical Evaluation of SON-1010 Dose Escalation Expanded with Atezolizumab in Ovarian Cancer August 5, 2025
First patient dosed in pivotal Ph 3 AK112-305/HARMONi-8A trial of ivonescimab + docetaxel for PD-1/L1i & chemo-refractory NSCLC August 5, 2025
Targeted Enrollment Completed for Lung Cancer Ph 2 Harmonic™ Trial in Japan for LP-300 August 5, 2025
CBX-663 nominated for the treatment of a broad range of solid tumor and heme malignancies July 29, 2025
First Patient Dosed in Ph 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors July 29, 2025
First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian Cancer July 29, 2025
ALKAZAR Ph 3 Trial of Neladalkib for Patients with TKI-naïve ALK-positive NSCLC initiated July 23, 2025
Elraglusib Clinical Program Advanced in Ewing Sarcoma After Positive Ph 1 Trial Demonstrates CRs and PRs in R/R Ewing Sarcoma July 23, 2025
First Patient Enrolled in Ph 3 AK112-312/HARMONi-GI6 Trial of Ivonescimab for 1L Metastatic CRC July 23, 2025
First patient dosed in NCI-sponsored pilot study of Pidnarulex (CX-5461) PD in patients with advanced solid tumors July 23, 2025
Dose Level 1 of ANGELICA TRIAL completed; Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Heme Malignancies July 23, 2025
CRC Cohort of Ph 2 Trial of PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results July 15, 2025
Enrollment completed in Ph 3 UTOPIA Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk NMIBC July 15, 2025
First patient dosed in the Ph 1 portion of Ph 1/2 trial of AVZO-1418/DB-1418 in patients with advanced solid tumors July 15, 2025
